-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 26, Winbond Health issued an announcement stating that its wholly-owned subsidiary Winbond Pharmaceuticals had recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for injection of methylprednisolone sodium succinate.
Methylprednisolone sodium succinate for injection is a kind of freeze-dried powder of glucocorticoid drugs.
According to the enlarged version of the hospital data (including urban public hospitals, county-level public hospitals, urban community hospitals, and township health centers) on Minai.
Winbond Pharmaceuticals, as the third company to pass the consistency evaluation of methylprednisolone sodium succinate (40mg) for injection, will be eligible to participate in the national centralized procurement